Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
50 studies found for:    ARSENIC ACID
Show Display Options
RSS Create an RSS feed from your search for:
ARSENIC ACID
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Assessing the Effectiveness of a Water Filter Technology as an Arsenic Mitigation Strategy in West Bengal
Conditions: Total Urinary Arsenic;   Total Arsenic in Water;   Diarrhoeal Disease
Intervention: Device: Pureit As+ Filter
2 Terminated
Has Results
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Interventions: Drug: Arsenic Trioxide (ATO);   Drug: Ascorbic Acid
3 Completed
Has Results
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid
4 Terminated Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Conditions: Essential Thrombocythemia;   Polycythemia Vera;   Primary Myelofibrosis
Interventions: Drug: Arsenic Trioxide;   Dietary Supplement: Ascorbic Acid;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
5 Recruiting Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA+arsenic;   Drug: ATRA+chemo
6 Terminated Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: ATO + Ascorbic acid
7 Terminated Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Arsenic Trioxide, Ascorbic Acid and Bortezomib
8 Completed
Has Results
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
Conditions: Multiple Myeloma;   Stem Cell Transplantation
Interventions: Drug: Arsenic Trioxide;   Drug: Melphalan;   Drug: Ascorbic Acid
9 Terminated Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: dexamethasone;   Drug: thalidomide
10 Completed All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: All-Trans Retinoic Acid (ATRA);   Drug: Arsenic Trioxide (ATO);   Drug: Idarubicin
11 Unknown  Effects of Folic Acid Supplementation on Arsenic Lowering
Conditions: Arsenic Poisoning;   Toxic Effect of Arsenic and Its Compounds
Intervention: Drug: folic acid supplementation
12 Completed Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide
13 Completed Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: bortezomib;   Drug: dexamethasone;   Drug: thalidomide;   Drug: Aspirin
14 Completed Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic
Condition: High Blood Arsenic Due to Chronic Arsenic Exposure
Interventions: Other: Placebo;   Dietary Supplement: folic acid;   Dietary Supplement: creatine;   Dietary Supplement: creatine + folic acid
15 Completed Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Condition: Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
Interventions: Drug: Arsenic Trioxide;   Drug: Decitabine
16 Completed Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: dexamethasone;   Drug: thalidomide
17 Withdrawn Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Refractory Plasma Cell Neoplasm
Interventions: Drug: arsenic trioxide;   Drug: ascorbic acid;   Drug: melphalan;   Procedure: chemosensitization/potentiation;   Procedure: chemotherapy
18 Withdrawn Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Refractory Plasma Cell Neoplasm
Interventions: Drug: arsenic trioxide;   Drug: ascorbic acid;   Drug: dexamethasone;   Drug: thalidomide;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological therapy;   Procedure: chemotherapy;   Procedure: drug resistance inhibition;   Procedure: growth factor antagonist therapy;   Procedure: non-specific immune-modulator therapy
19 Completed Effect of Spirulina on Zinc, Vitamin E and Linoleic Acid Levels in Palm Skin Following Chronic Exposure to Arsenic
Condition: Arsenical Keratosis
Intervention: Dietary Supplement: Spirulina
20 Completed
Has Results
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Condition: Myeloma
Interventions: Drug: Trisenox (Arsenic Trioxide);   Drug: Velcade (Bortezomib);   Drug: Melphalan;   Drug: Vitamin C (Ascorbic Acid)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.